These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
224 related articles for article (PubMed ID: 18768809)
41. Distinct roles for mammalian target of rapamycin complexes in the fibroblast response to transforming growth factor-beta. Rahimi RA; Andrianifahanana M; Wilkes MC; Edens M; Kottom TJ; Blenis J; Leof EB Cancer Res; 2009 Jan; 69(1):84-93. PubMed ID: 19117990 [TBL] [Abstract][Full Text] [Related]
42. Chromosomal instability by beta-catenin/TCF transcription in APC or beta-catenin mutant cells. Aoki K; Aoki M; Sugai M; Harada N; Miyoshi H; Tsukamoto T; Mizoshita T; Tatematsu M; Seno H; Chiba T; Oshima M; Hsieh CL; Taketo MM Oncogene; 2007 May; 26(24):3511-20. PubMed ID: 17160019 [TBL] [Abstract][Full Text] [Related]
43. Potentiation of Growth Inhibitory Responses of the mTOR Inhibitor Everolimus by Dual mTORC1/2 Inhibitors in Cultured Breast Cancer Cell Lines. Leung EY; Askarian-Amiri M; Finlay GJ; Rewcastle GW; Baguley BC PLoS One; 2015; 10(7):e0131400. PubMed ID: 26148118 [TBL] [Abstract][Full Text] [Related]
44. Wnt signaling regulates Snai1 expression and cellular localization in the mouse intestinal epithelial stem cell niche. Horvay K; Casagranda F; Gany A; Hime GR; Abud HE Stem Cells Dev; 2011 Apr; 20(4):737-45. PubMed ID: 20670162 [TBL] [Abstract][Full Text] [Related]
45. Elevation of n-3/n-6 PUFAs ratio suppresses mTORC1 and prevents colorectal carcinogenesis associated with APC mutation. Liu M; Zhou L; Zhang B; He M; Dong X; Lin X; Jia C; Bai X; Dai Y; Su Y; Zou Z; Zheng H Oncotarget; 2016 Nov; 7(47):76944-76954. PubMed ID: 27769066 [TBL] [Abstract][Full Text] [Related]
46. The mTORC1 inhibitor everolimus prevents and treats Eμ-Myc lymphoma by restoring oncogene-induced senescence. Wall M; Poortinga G; Stanley KL; Lindemann RK; Bots M; Chan CJ; Bywater MJ; Kinross KM; Astle MV; Waldeck K; Hannan KM; Shortt J; Smyth MJ; Lowe SW; Hannan RD; Pearson RB; Johnstone RW; McArthur GA Cancer Discov; 2013 Jan; 3(1):82-95. PubMed ID: 23242809 [TBL] [Abstract][Full Text] [Related]
47. PIK3CA mutation, but not PTEN loss of function, determines the sensitivity of breast cancer cells to mTOR inhibitory drugs. Weigelt B; Warne PH; Downward J Oncogene; 2011 Jul; 30(29):3222-33. PubMed ID: 21358673 [TBL] [Abstract][Full Text] [Related]
52. Cyclin D1 genetic heterozygosity regulates colonic epithelial cell differentiation and tumor number in ApcMin mice. Hulit J; Wang C; Li Z; Albanese C; Rao M; Di Vizio D; Shah S; Byers SW; Mahmood R; Augenlicht LH; Russell R; Pestell RG Mol Cell Biol; 2004 Sep; 24(17):7598-611. PubMed ID: 15314168 [TBL] [Abstract][Full Text] [Related]
53. Endothelial Cell mTOR Complex-2 Regulates Sprouting Angiogenesis. Farhan MA; Carmine-Simmen K; Lewis JD; Moore RB; Murray AG PLoS One; 2015; 10(8):e0135245. PubMed ID: 26295809 [TBL] [Abstract][Full Text] [Related]
54. APC and oncogenic KRAS are synergistic in enhancing Wnt signaling in intestinal tumor formation and progression. Janssen KP; Alberici P; Fsihi H; Gaspar C; Breukel C; Franken P; Rosty C; Abal M; El Marjou F; Smits R; Louvard D; Fodde R; Robine S Gastroenterology; 2006 Oct; 131(4):1096-109. PubMed ID: 17030180 [TBL] [Abstract][Full Text] [Related]
55. Loss of mTOR signaling affects cone function, cone structure and expression of cone specific proteins without affecting cone survival. Ma S; Venkatesh A; Langellotto F; Le YZ; Hall MN; Rüegg MA; Punzo C Exp Eye Res; 2015 Jun; 135():1-13. PubMed ID: 25887293 [TBL] [Abstract][Full Text] [Related]
56. Up-regulation of CYP26A1 in adenomatous polyposis coli-deficient vertebrates via a WNT-dependent mechanism: implications for intestinal cell differentiation and colon tumor development. Shelton DN; Sandoval IT; Eisinger A; Chidester S; Ratnayake A; Ireland CM; Jones DA Cancer Res; 2006 Aug; 66(15):7571-7. PubMed ID: 16885356 [TBL] [Abstract][Full Text] [Related]
57. Regulation of androgen receptor transcriptional activity by rapamycin in prostate cancer cell proliferation and survival. Wang Y; Mikhailova M; Bose S; Pan CX; deVere White RW; Ghosh PM Oncogene; 2008 Nov; 27(56):7106-17. PubMed ID: 18776922 [TBL] [Abstract][Full Text] [Related]
58. mTORC1 Up-Regulates GP73 to Promote Proliferation and Migration of Hepatocellular Carcinoma Cells and Growth of Xenograft Tumors in Mice. Chen X; Wang Y; Tao J; Shi Y; Gai X; Huang F; Ma Q; Zhou Z; Chen H; Zhang H; Liu Z; Sun Q; Peng H; Chen R; Jing Y; Yang H; Mao Y; Zhang H Gastroenterology; 2015 Sep; 149(3):741-52.e14. PubMed ID: 25980751 [TBL] [Abstract][Full Text] [Related]
59. mTORC1 activation regulates beta-cell mass and proliferation by modulation of cyclin D2 synthesis and stability. Balcazar N; Sathyamurthy A; Elghazi L; Gould A; Weiss A; Shiojima I; Walsh K; Bernal-Mizrachi E J Biol Chem; 2009 Mar; 284(12):7832-42. PubMed ID: 19144649 [TBL] [Abstract][Full Text] [Related]
60. Selective pharmacogenetic inhibition of mammalian target of Rapamycin complex I (mTORC1) blocks long-term synaptic plasticity and memory storage. Stoica L; Zhu PJ; Huang W; Zhou H; Kozma SC; Costa-Mattioli M Proc Natl Acad Sci U S A; 2011 Mar; 108(9):3791-6. PubMed ID: 21307309 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]